Merck announced today that the Centers for Disease Control’s Advisory Committee on Immunization Practices is now strongly recommending that adults aged sixty and older receive Merck’s Zostavax vaccine against shingles (herpes zoster). This recommendation follows the FDA’s approval of the vaccine which was given last May. FEHB plans generally adopt the Advisory Committee’s recommendations. Merck charges $150 per dose for the one shot vaccine.